Adverum Biotechnologies ADVM

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
-$0.05 (-1.08%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

Business overview of Adverum Biotechnologies (ADVM)
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.

Key Insights

Critical company metrics and information

  • Latest Closing Price

    $4.58

  • Market Cap

    $95.28 Million

  • Price-Earnings Ratio

    -3.52

  • Total Outstanding Shares

    20.80 Million Shares

  • Total Employees

    121

  • Dividend

    No dividend

  • IPO Date

    July 31, 2014

  • SIC Description

    Biological Products, (no Disgnostic Substances)

  • Primary Exchange

    NASDAQ

  • Type

    Common Stock

  • Headquarters

    100 cardinal way, Redwood city, CA, 94063

  • Homepage

    https://www.adverum.com

Historical Stock Splits

If you bought 10 shares of ADVM before March 21, 2024, you'd have 1 share today.
Execution DateSplit Amount
March 21, 20241-for-10 (Reverse Split)

Cash Flow Statement

July 1, 2024 to September 30, 2024
MetricValue
Net Cash Flow From Financing Activities, Continuing$0
Net Cash Flow, Continuing$-34.47 Million
Net Cash Flow From Investing Activities, Continuing$-13.35 Million
Net Cash Flow From Investing Activities$-13.35 Million
Net Cash Flow From Operating Activities, Continuing$-21.12 Million
Net Cash Flow From Operating Activities$-21.12 Million

Income Statement

July 1, 2024 to September 30, 2024
MetricValue
Benefits Costs and Expenses$28.13 Million
Nonoperating Income/Loss$2.09 Million
Depreciation and Amortization$890,000
Diluted Average Shares$20.88 Million
Operating Expenses$30.22 Million
Other Operating Expenses$9.78 Million

Comprehensive Income

July 1, 2024 to September 30, 2024
MetricValue
Other Comprehensive Income/Loss$-26.88 Million
Comprehensive Income/Loss Attributable To Parent$-26.88 Million
Comprehensive Income/Loss$-26.88 Million
Comprehensive Income/Loss Attributable To Noncontrolling Interest$0

Balance Sheet

July 1, 2024 to September 30, 2024
MetricValue
Other Current Liabilities$25.55 Million
Current Liabilities$27.66 Million
Fixed Assets$12.21 Million
Current Assets$161.08 Million
Equity$144.12 Million
Accounts Payable$2.11 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Recent Headlines From The Web

Latest news, press releases, and media coverage about ADVM from trusted financial sources
    All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

    â“’ 2025 Financhle. All Rights Reserved.